Cargando…
Therapeutics of Alzheimer’s Disease: Recent Developments
With increasing aging, dementia is a growing public health concern globally. Patients with dementia have multiple psychological and behavioral changes, including depression, anxiety, inappropriate behavior, paranoia, agitation, and hallucinations. The major types of dementia are Alzheimer’s disease...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774459/ https://www.ncbi.nlm.nih.gov/pubmed/36552610 http://dx.doi.org/10.3390/antiox11122402 |
_version_ | 1784855413212053504 |
---|---|
author | Burns, Scott Selman, Ashley Sehar, Ujala Rawat, Priyanka Reddy, Arubala P. Reddy, P. Hemachandra |
author_facet | Burns, Scott Selman, Ashley Sehar, Ujala Rawat, Priyanka Reddy, Arubala P. Reddy, P. Hemachandra |
author_sort | Burns, Scott |
collection | PubMed |
description | With increasing aging, dementia is a growing public health concern globally. Patients with dementia have multiple psychological and behavioral changes, including depression, anxiety, inappropriate behavior, paranoia, agitation, and hallucinations. The major types of dementia are Alzheimer’s disease (AD), vascular dementia (VCID), Lewy body dementia (LBD), frontotemporal dementia (FTD), and mixed dementia (MiAD). Among these, AD is the most common form of dementia in the elderly population. In the last three decades, tremendous progress has been made in understanding AD’s biology and disease progression, particularly its molecular basis, biomarker development, and drug discovery. Multiple cellular changes have been implicated in the progression of AD, including amyloid beta, phosphorylated tau, synaptic damage, mitochondrial dysfunction, deregulated microRNAs, inflammatory changes, hormonal deregulation, and others; based on these changes, therapeutic strategies have been developed, which are currently being tested in animal models and human clinical trials. The purpose of our article is to highlight recent therapeutic strategies’ developments, critically discuss current strategies’ failures, and propose new strategies to combat this devasting mental illness. |
format | Online Article Text |
id | pubmed-9774459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97744592022-12-23 Therapeutics of Alzheimer’s Disease: Recent Developments Burns, Scott Selman, Ashley Sehar, Ujala Rawat, Priyanka Reddy, Arubala P. Reddy, P. Hemachandra Antioxidants (Basel) Review With increasing aging, dementia is a growing public health concern globally. Patients with dementia have multiple psychological and behavioral changes, including depression, anxiety, inappropriate behavior, paranoia, agitation, and hallucinations. The major types of dementia are Alzheimer’s disease (AD), vascular dementia (VCID), Lewy body dementia (LBD), frontotemporal dementia (FTD), and mixed dementia (MiAD). Among these, AD is the most common form of dementia in the elderly population. In the last three decades, tremendous progress has been made in understanding AD’s biology and disease progression, particularly its molecular basis, biomarker development, and drug discovery. Multiple cellular changes have been implicated in the progression of AD, including amyloid beta, phosphorylated tau, synaptic damage, mitochondrial dysfunction, deregulated microRNAs, inflammatory changes, hormonal deregulation, and others; based on these changes, therapeutic strategies have been developed, which are currently being tested in animal models and human clinical trials. The purpose of our article is to highlight recent therapeutic strategies’ developments, critically discuss current strategies’ failures, and propose new strategies to combat this devasting mental illness. MDPI 2022-12-03 /pmc/articles/PMC9774459/ /pubmed/36552610 http://dx.doi.org/10.3390/antiox11122402 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Burns, Scott Selman, Ashley Sehar, Ujala Rawat, Priyanka Reddy, Arubala P. Reddy, P. Hemachandra Therapeutics of Alzheimer’s Disease: Recent Developments |
title | Therapeutics of Alzheimer’s Disease: Recent Developments |
title_full | Therapeutics of Alzheimer’s Disease: Recent Developments |
title_fullStr | Therapeutics of Alzheimer’s Disease: Recent Developments |
title_full_unstemmed | Therapeutics of Alzheimer’s Disease: Recent Developments |
title_short | Therapeutics of Alzheimer’s Disease: Recent Developments |
title_sort | therapeutics of alzheimer’s disease: recent developments |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774459/ https://www.ncbi.nlm.nih.gov/pubmed/36552610 http://dx.doi.org/10.3390/antiox11122402 |
work_keys_str_mv | AT burnsscott therapeuticsofalzheimersdiseaserecentdevelopments AT selmanashley therapeuticsofalzheimersdiseaserecentdevelopments AT seharujala therapeuticsofalzheimersdiseaserecentdevelopments AT rawatpriyanka therapeuticsofalzheimersdiseaserecentdevelopments AT reddyarubalap therapeuticsofalzheimersdiseaserecentdevelopments AT reddyphemachandra therapeuticsofalzheimersdiseaserecentdevelopments |